

# AAX Biotech announces collaboration with research group at Karolinska Institutet on high-throughput characterization of novel TROP2-targeting antibodies

Biotech company AAX Biotech, a leading innovator in technologies for antibody-based therapies, today announced a new collaboration with the research group of Dr. Thuy Tran at the Department of Oncology-Pathology, Karolinska Institutet. AAX Biotech will leverage its Seqitope® platform and automation infrastructure to characterize novel anti-TROP2 antibodies developed by the Tran group and elucidate the molecular features that differentiate them from established TROP2 binders.

“*Seqitope® allows us to compare large panels of antibodies in parallel and characterize their molecular binding profiles at high resolution.*”

- Daniel X Johansson, CEO and CSO of AAX Biotech



TROP2 (Trophoblast cell surface antigen 2) is a clinically validated cancer target, yet characterizing therapies directed against it remains notoriously difficult. Its complex structure and tendency to pair on the cell surface make it challenging to determine exactly how antibodies engage TROP2. This insight is critical to identifying candidates with therapeutic potential.

The Tran group has generated anti-TROP2 antibodies with unique properties and improved profiles relative to existing TROP2 binders. Under the collaboration, AAX Biotech will apply Seqitope® to map the antibodies' epitopes at high resolution and characterize them alongside benchmark molecules, providing molecular-level insight into the properties that differentiate them from established TROP2 binders. With Seqitope® and its robotic platform, AAX Biotech can characterize up to 100 antibodies in parallel, supporting both detailed candidate analysis and broader panel screening.

“Seqitope® allows us to compare large panels of antibodies in parallel and characterize their molecular binding profiles at high resolution,” said Daniel X Johansson, CEO and CSO of AAX Biotech. “By analyzing multiple TROP2 binders side by side, we hope to better understand the molecular characteristics associated with different therapeutic properties.”

“Our group has generated anti-TROP2 antibodies with unique properties and qualities that, in our hands, exceed those of existing TROP2 binders. Through this collaboration with AAX Biotech, Seqitope® will allow us to elucidate at the molecular level what sets our antibodies apart, an insight that is essential as we advance them towards therapeutic application,” said Thuy Tran, research group leader at the Department of Oncology-Pathology, Karolinska Institutet.

**For more information, please contact:**

Maria Lisa Knudsen, CBO

[maria.knudsen@aaxbiotech.com](mailto:maria.knudsen@aaxbiotech.com)

**About AAX Biotech AB**

AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics.

The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb®, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by Daniel X Johansson and Mats AA Persson from Karolinska Institutet in Stockholm, Sweden. Visit [aaxbiotech.com](http://aaxbiotech.com) to learn more and follow [AAX Biotech on LinkedIn](#).